Effects of chronic treatment with metformin on dipeptidyl peptidase‐4 activity, glucagon‐like peptide 1 and ghrelin in obese patients with type 2 diabetes mellitus
SK Thondam, A Cross, DJ Cuthbertson… - Diabetic …, 2012 - Wiley Online Library
SK Thondam, A Cross, DJ Cuthbertson, JP Wilding, C Daousi
Diabetic Medicine, 2012•Wiley Online LibraryDiabet. Med. 29, e205–e210 (2012) Abstract Aims Studies investigating the acute effects of
metformin have demonstrated actions on the incretin system and appetite regulatory
hormones. There are limited data to support that these effects are sustained in the long term.
We therefore studied the effects of chronic treatment with metformin on endogenous
glucagon‐like peptide 1, dipeptidyl peptidase‐4 activity and active ghrelin (an orexigenic
hormone) in obese patients with Type 2 diabetes mellitus. Methods Eight subjects [six male …
metformin have demonstrated actions on the incretin system and appetite regulatory
hormones. There are limited data to support that these effects are sustained in the long term.
We therefore studied the effects of chronic treatment with metformin on endogenous
glucagon‐like peptide 1, dipeptidyl peptidase‐4 activity and active ghrelin (an orexigenic
hormone) in obese patients with Type 2 diabetes mellitus. Methods Eight subjects [six male …
Diabet. Med. 29, e205–e210 (2012)
Abstract
Aims Studies investigating the acute effects of metformin have demonstrated actions on the incretin system and appetite regulatory hormones. There are limited data to support that these effects are sustained in the long term. We therefore studied the effects of chronic treatment with metformin on endogenous glucagon‐like peptide 1, dipeptidyl peptidase‐4 activity and active ghrelin (an orexigenic hormone) in obese patients with Type 2 diabetes mellitus.
Methods Eight subjects [six male, age 58.7 ± 2.6 years, BMI 41.1 ± 2.9 kg/m2, HbA1c 69 ± 6 mmol/mol (8.5 ± 0.5%), mean ± sem] with drug‐naļve Type 2 diabetes were studied for 6 h following a standard mixed meal, before and after at least 3 months of metformin monotherapy (mean dose 1.75 g daily).
Results The area under the curve (AUC0–6 h) for active glucagon‐like peptide 1 was significantly higher on metformin (pre‐metformin 1750.8 ± 640 pmol l−1 min−1 vs. post‐metformin 2718.8 ± 1182.3 pmol l−1 min−1; P = 0.01). The areas under the curves for dipeptidyl peptidase‐4 activity and ghrelin were not significantly different pre‐ and post‐treatment with metformin.
Conclusion Three months or more of metformin monotherapy in obese patients with Type 2 diabetes was associated with increased postprandial active glucagon‐like peptide 1 levels. The effects of metformin on the enteroinsular axis may represent yet another important mechanism underlying its glucose‐lowering effects.
Wiley Online Library